Anti-IL-17 a New Treatment for Contact Dermatititis
- Sponsor
- Tanja Todberg, MD
- Study ID
- NCT02778711
- Phase
- PHASE3
- Status
- Unknown
Conditions
- Allergic Contact Dermatitits
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 100 Years
- Healthy Volunteers
- Accepted
Interventions
- secukinumab — DRUGanti-IL-17
Study Details
The purpose of this study is to assess the efficacy of anti-IL 17 treatment (secukinumab) in patients with known severe allergic contact dermatitis (ACD).
Key Dates
- Start date
- Jan 31, 2016
- Status verified
- May 2016
- Primary completion
- Jun 30, 2017
- Completion
- Jun 30, 2017
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Cosentyxsecukinumab (anti-IL-17)
Primary Outcome Measure
1. Reduction in clinical patch test score for dermatitis after secukinumab treatment compared to patch test score before treatment (study 1) [ Time Frame: 18 months ]